查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1178166

多形性胶质母细胞瘤治疗的全球市场:市场规模 - 各药物类别，各治疗法，各最终用途，各地区展望，竞争策略，各市场区隔预测(～2032年)

Glioblastoma Multiforme Treatment Market Size- By Drug Class, By Treatment, By End Use - Regional Outlook, Competitive Strategies and Segment Forecasts to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 225 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球多形性胶质母细胞瘤治疗的市场规模，预计至2032年达到60亿5,000万美元，以9.04％的年复合成长率成长。

由于研究开发的活跃，良好的法规环境，多形性胶质母细胞瘤的发生率上升等各种要素，预计市场扩大。强力的开发平台，预计在预测期间内给予市场大幅影响。

本报告提供全球多形性胶质母细胞瘤治疗市场相关调查，市场动态，市场变数与展望，各药物类别、治疗方法、最终用途、地区的市场分析，企业简介等相关资讯。

目录

第1章 简介

  • 调查范围
  • 市场区隔分析

第2章 调查手法

  • 调查资料来源
  • 市场规模的估计
  • 资料的三角测量

第3章 摘要整理

第4章 市场动态

  • 促进因素，阻碍因素，机会，课题的分析
    • 促进因素
    • 阻碍因素
    • 机会
    • 课题
  • 多形性胶质母细胞瘤治疗市场上COVID-19的影响

第5章 市场变数与展望

  • SWOT分析
    • 优势
    • 弱点
    • 机会
    • 威胁
  • PESTEL分析
    • 政治形势
    • 经济形势
    • 社会形势
    • 技术形势
    • 环境形势
    • 法律上的形势
  • 波特的五力分析
    • 供给企业谈判力
    • 买方议价能力
    • 替代品的威胁
    • 新加入厂商的威胁
    • 竞争企业间的敌对关係
  • 热图分析

第6章 全球多形性胶质母细胞瘤治疗市场:各药物类别(2019年～2032年(100万美元))

  • Bevacizumab
  • Carmustine Wafers
  • Lomustine
  • Temozolomide
  • 其他

第7章 全球多形性胶质母细胞瘤治疗市场:各治疗法(2019年～2032年(100万美元))

  • 化疗
  • 免疫疗法
  • 放射线治疗
  • 手术
  • 标靶治疗
  • 肿瘤治疗领域(TTF)疗法

第8章 全球多形性胶质母细胞瘤治疗市场:各最终用途(2019年～2032年(100万美元))

  • 门诊病人手术中心
  • 诊疗所
  • 医院

第9章 全球多形性胶质母细胞瘤治疗市场:各地区(2019年～2032年(100万美元))

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 其他的亚太地区
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中东、非洲
    • 沙乌地阿拉伯王国
    • 阿拉伯联合大公国
    • 其他的中东、非洲

第10章 企业简介

  • Amgen, Inc.
    • 企业概要
    • 财务展望
    • 产品概要
    • 最近的开发
  • Amneal Pharmaceuticals
  • Arbor Pharmaceuticals, LLC
  • F. Hoffmann-La Roche
  • Karyopharm Therapeutics, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sumitomo Dainippon Pharma Oncology Inc. (Boston Biomedical Inc.)
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd
简介目录
Product Code: HLCA2229

Global Glioblastoma Multiforme Treatment Market Overview:

According to SPER Market Research, the Global Glioblastoma Multiforme Treatment Market is estimated to reach USD 6.05 billion by 2032 with a CAGR of 9.04%.

Glioblastoma multiforme (GBM) is an astrocytic-differentiated malignant tumour classified by the WHO as grade IV. The description and development of theories about these tumours have been covered in a wide range of historical records since they are among the most frequently clinically diagnosed central nervous system (CNS) oncological entry.The market is anticipated to grow as a result of a number of factors, including increased R&D, favourable regulatory settings, and the rising occurrence of glioblastoma multiforme. A strong pipeline is likely to significantly influence the glioblastoma multiforme (GBM) therapeutic market during the projected timeframe. It is estimated that the occurrence of brain tumours will drive market expansion throughout the course of the anticipated timeframe.The market is predicted to be boosted in the coming years by the growing acceptance of novel medicines and combination therapies. The need for a personalised treatment strategy to handle glioblastoma multiforme is anticipated to rise as a result of tumour heterogeneity and variance in patient-to-patient treatment approaches. The approval of new therapies is anticipated to lengthen the life expectancy of glioblastoma multiforme patients.

Impact of COVID-19 on the Global Glioblastoma Multiforme Treatment Market

The market for glioblastoma treatments has suffered as a result of COVID-19. During the COVID-19 pandemic, many ICU resources, including ventilators, personal protective equipment, and medical personnel, were diverted to COVID-19 cases, leading to the cessation of surgical neuro-oncology treatments. During the pandemic, there was instability in the ability to provide essential cancer patients with effective medical care. Additionally, it appears that individuals with glioblastoma are more susceptible to the COVID-19 infection, which led to the cancellation of surgeries and therapies. The worldwide glioma treatment market consequently has a significant impact on the market.

Scope of the Report:

Market size available for years 2019-2032

Base year considered 2021

Forecast period 2022-2032

Segments covered By Drug Class, By Treatment, By End Use

Regions covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Covered Amgen, Inc., Amneal Pharmaceuticals, Arbor Pharmaceuticals, LLC, F. Hoffmann-La Roche Ltd., Karyopharm Therapeutics, Inc., Merck & Co., Inc., Pfizer Inc., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.), Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd

Global Glioblastoma Multiforme Treatment Market Segmentation:

By Drug Class: Based on the Drug Class, Global Glioblastoma Multiforme Treatment Market is segmented as; Bevacizumab, Carmustine Wafers, Lomustine, Temozolomide, Others.

By Treatment: Based on the Treatment, Global Glioblastoma Multiforme Treatment Market is segmented as; Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, Targeted Therapy, Tumor Treating Field (TTF) Therapy.

By End Use: Based on the End Use, Global Glioblastoma Multiforme Treatment Market is segmented as; Ambulatory Surgical Centres, Clinics, Hospitals.

By Region: North America accounted for the largest percentage in recent years. Government support for the expansion of the healthcare sector, together with increased awareness of unusual ailments, simple access to top-notch medical facilities, and kind reimbursement policies, are some of the key factors driving regional market growth. Asia Pacific is anticipated to grow at the fastest rate throughout the projection period due to a number of factors, including the introduction of temozolomide generics, an improved economy, an increase in the world's elderly population, and rising healthcare investment.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Glioblastoma Multiforme Treatment Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Glioblastoma Multiforme Treatment Market, By Drug Class, 2019-2032 (USD Million)

  • 6.1. Bevacizumab
  • 6.2. Carmustine Wafers
  • 6.3. Lomustine
  • 6.4. Temozolomide
  • 6.5. Others

7. Global Glioblastoma Multiforme Treatment Market, By Treatment, 2019-2032 (USD Million)

  • 7.1. Chemotherapy
  • 7.2. Immunotherapy
  • 7.3. Radiation Therapy
  • 7.4. Surgery
  • 7.5. Targeted Therapy
  • 7.6. Tumor Treating Field (TTF) Therapy

8. Global Glioblastoma Multiforme Treatment Market, By End Use, 2019-2032 (USD Million)

  • 8.1. Ambulatory Surgical Centers
  • 8.2. Clinics
  • 8.3. Hospitals

9. Global Glioblastoma Multiforme Treatment Market, By Region, 2019-2032 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. Amgen, Inc.
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Amneal Pharmaceuticals
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. Arbor Pharmaceuticals, LLC
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. F. Hoffmann-La Roche
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. Karyopharm Therapeutics, Inc.
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6. Merck & Co., Inc.
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Pfizer Inc.
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. Sumitomo Dainippon Pharma Oncology Inc. (Boston Biomedical Inc.)
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.9. Sun Pharmaceutical Industries Ltd.
    • 10.9.1. Company details
    • 10.9.2. Financial outlook
    • 10.9.3. Product summary
    • 10.9.4. Recent developments
  • 10.10. Teva Pharmaceutical Industries Ltd.
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments